Weikang Pill Role And Mechanism Of Helicobacter Pylori Resistance And Anti-demolition Party Jinghuaweikang

Systematic Review:Meta-analysis of Jinghua Weikang capsules combined PPI triple therapy on Helicobacter pylori infectionObjective:Systematic review of the difference of efficacy and adverse reactionsbetween Jing Hua Wei Kang capsule combined PPI triple therapy and triple therapy alone on Helicobacter pylori infection.Methods:We searched PubMed, Cochrane Library, EMBASE, Web of Science, CNKI, VIP and the Chinese Medical Association digital journal library for randomized controlled trial comparing Jinghua Weikang Capsules combined triple therapy vs. triple therapy alone, with retrieval time from the built of the library till February2013, and traced the literature references. According to the inclusion criteria literatures were selected independently by two researchers and data was extracted. The methodological quality of the included studies were evaluated according to the Jadad scoring criteria. Meta-analysis was conducted with RevMan5.0software.Results:A total of14studies and1619patients were included. Meta-analysis showed:H. pylori eradication rate of Jinghua Weikang capsules combined PPI triple therapy vs. PPI triple therapy alone [OR=3.29,95%CI (2.44,4.44), P<0.00001];8studies reported incidence of adverse reactions, incidence of adverse reactions of the two groups was no significant difference; adverse reactions reported were mild.Conclusion:The present studies showed that the Helicobacter pylori infection eradication rate of Jinghua Weikang capsules with PPI triple therapy was better than PPI triple with mild adverse reactions. Experiment1:The bactericidal action of pharmaceutical raw materials of Jinghua Weikang Capsule and its main components on resistant Helicobacter pylori in vitroObjective:To confirm the bactericidal action of pharmaceutical raw materials of Jing Weikang Capsule and its main components on resistant Helicobacter pylori, and their synergistic effect when combining with antibiotics.Methods:E-test method was used for screening of resistance of clinical isolates.The minimum inhibitory concentration (MIC) of Jing WeikangCapsule and its main ingredients drug Chenopodium ambrosioides L. and pilular adinawere determined with the agar dilution method.By the way of in vitro bactericidal experiments, time-killing curveof Jinghua Weikangand its main ingredients Chenopodium ambrosioides L. and pilular adina alone on resistant Hp were measured at different concentrations.The synergy effect of metronidazoleor clarithromycin combined with Jinghua Weikang Capsule, Chenopodium ambrosioides L. or pilular adina were also analyzed with time-killing curve.Results:Jinghua Weikang Capsuleand Chenopodium ambrosioides L. had an obvious bactericidal effecton clinical drug resistant Hp in vitro at1/2times of the MIC concentration.The bactericidal effect increasedin dose and time dependent manner. In combination withJinghua Weikangor Chenopodium ambrosioides L., the in vitro bactericidal effect of metronidazole or clarithromycin on clinical resistantHp has been strengthened. The bactericidal effect of Jinghua Weikang’s another ingredient pilular adina is not obvious.Conclusion:Jinghua Weikang Capsule and Chenopodium ambrosioides L. APIs had a bactericidal effect on resistant Hp, and its bactericidal effect increased with dose and time, andthe strengthen the bactericidal effect was enhanced in combination with the antibiotic. Experiment2:Role ofChenopodium ambrosioides L. extract on efflux pump hefABCgene expression of drug-resistant Helicobacter pylori strainsObjective:To study Jinghua Weikang capsule’s main component Chenopodium ambrosioides L.on efflux pump hefABC gene expression of drug-resistant Helicobacter pylori strains, explore molecular mechanisms of Chenopodium ambrosioides L. anti-drug-resistant H pylori.METHODS:The experiment strains H. pylori NCTC11637and three clinical strains were selected from the department of gastroenterology laboratory of Peking University First Hospital saved strains, the clinical drug-resistant strains were confirmed by E-test (AB Biodisk Solna, Sweden) susceptibility test for detection of resistance to commonly used antibiotics. The minimum inhibitory concentration (MIC) of the Chenopodium ambrosioides L. volatile oil on H. pylori were determined byagar dilution method.Put fresh H. pylori strains cultured about48-72h intobrucella broth containing10%fetal bovine serum for shaking culturing, at37°C, in micro-aerobic environment. The broth was divided into6parts. Chenopodium ambrosioides L. were added into5parts, andthe concentration of the drug were as follows respectively,1/8,1/4,1/2,1and2times of the MIC. Collected the strains at3h after culturing. RNA extraction RNA was extracted by Trizol extraction kit Operating Instructions. The quality of the extracted RNA was identified by the A260/A280ratio and1.5%agarose gel electrophoresis. Oligo dT primers were used in RT reverse transcription. The amount of gene expression of each sample’s hefA, hefB and hefC were determinated by quantitative PCR reaction, which were expressed by2-△△Ct.Results:Compared with the control group, when added of Chenopodium ambrosioides L.,the amount of genes expression of hefA, hefB and hefC decreased in each group. The genes expression were inhibited obviouslyat1/2MIC concentration of Chenopodium ambrosioides L.Conclusion:Chenopodium ambrosioides L. can downgradegene expression of resistant Helicobacter pylori efflux pump hefABC, which may be the molecular mechanism of the drug anti resistant Helicobacter pylori strains.